View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Jan. 31, 2017	Mar. 07, 2017
Document And Entity Information
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Document Type	10-Q
Document Period End Date	Jan. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		40,295,359
Trading Symbol	ADXS
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2017

Condensed Balance Sheets - USD ($)	Jan. 31, 2017	Oct. 31, 2016
Current Assets:
Cash and Cash Equivalents	$ 57,566,606	$ 112,750,980
Investments - Held-to-Maturity	79,295,379	39,336,548
Interest Receivable	180,964	80,142
Prepaid Expenses	577,770	812,830
Income Tax Receivable		2,549,862
Deferred Expenses - current	4,435,025	4,291,385
Other Current Assets	132,797	53,451
Total Current Assets	142,188,541	159,875,198
Property and Equipment (net of accumulated depreciation)	5,242,857	4,389,074
Intangible Assets (net of accumulated amortization)	4,336,143	4,329,121
Other Assets	426,287	450,667
TOTAL ASSETS	152,193,828	169,044,060
Current Liabilities:
Accounts Payable	3,534,440	1,720,428
Accrued Expenses	7,676,443	10,905,003
Deferred Revenue	14,047,906	15,020,576
Lease Incentive Obligation	40,226	40,226
Common Stock Warrant Liability	10,652	20,156
Total Current Liabilities	25,309,667	27,706,389
Deferred Rent	534,160	475,749
Deferred Revenue	18,666,396	21,234,568
Lease Incentive Obligation- net of current portion	315,104	325,160
Total Liabilities	44,825,327	49,741,866
Commitments and Contingencies
Shareholders' Equity:
Preferred Stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at January 31, 2017 and October 31, 2016. Liquidation preference of $0 at January 31, 2017 and October 31, 2016.
Common Stock - $0.001 par value; 65,000,000 shares authorized, 40,186,693 shares issued and outstanding at January 31, 2017 and 40,057,067 shares issued and 40,041,047 shares outstanding at October 31, 2016.	40,187	40,057
Additional Paid-In Capital	332,116,142	327,098,749
Treasury Stock, at cost, 0 shares at January 31, 2017 and 16,020 shares October 31, 2016		(129,787)
Accumulated Deficit	(224,787,828)	(207,706,825)
Total Shareholders' Equity	107,368,501	119,302,194
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 152,193,828	$ 169,044,060

Condensed Balance Sheets (Parenthetical) - USD ($)	Jan. 31, 2017	Oct. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Series B Preferred stock, shares issued	0	0
Series B Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	65,000,000	65,000,000
Common stock, shares issued	40,186,693	40,057,067
Common stock, shares outstanding	40,186,693	40,041,047
Treasury Stock, shares	0	16,020

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
Income Statement [Abstract]
Revenue	$ 3,790,842	$ 250,000
Operating Expenses
Research and Development Expenses	13,648,554	13,064,954
General and Administrative Expenses	7,327,809	7,136,823
Total Operating Expenses	20,976,363	20,201,777
Loss from Operations	(17,185,521)	(19,951,777)
Other Income (Expense):
Interest Income	145,137	71,800
Net Changes in Fair Value of Derivative Liabilities	9,504	49,282
Other Income (Expense), Net	(123)	(4)
Loss before benefit for income taxes	(17,031,003)	(19,830,699)
Income Tax Expense	50,000	14,236
Net Loss	$ (17,081,003)	$ (19,844,935)
Net Loss Per Share, Basic and Diluted	$ (0.43)	$ (0.59)
Weighted Average Number of Shares Outstanding, Basic and Diluted	40,115,178	33,684,715

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
OPERATING ACTIVITIES
Net loss	$ (17,081,003)	$ (19,844,935)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation	5,110,425	9,529,008
(Gain) on change in fair value of derivative liabilities	(9,504)	(49,282)
Employee stock purchase plan	67,923	9,673
Depreciation expense	157,580	46,034
Amortization of intangible assets	74,410	57,946
Deferred rent	58,411	11,182
Lease incentive obligation	(10,056)
Amortization of premium on held to maturity investments	44,005	82,491
Change in operating assets and liabilities:
Interest receivable	(100,822)	(7,008)
Prepaid expenses	235,060	132,075
Income tax receivable	2,549,862	1,609,349
Other current assets	(79,346)	(135,823)
Deferred expenses	(143,640)	569,284
Other assets	24,380	(152,375)
Accounts payable and accrued expenses	(1,454,011)	3,250,088
Deferred revenue	(3,540,842)
Net cash used in operating activities	(14,097,168)	(4,892,293)
INVESTING ACTIVITIES
Purchases of held to maturity investments	(46,525,169)	(5,068,339)
Proceeds from maturities and redemptions on held to maturity investments	6,522,333	2,450,000
Purchase of property and equipment	(1,127,000)	(445,197)
Cost of intangible assets	(81,432)	(170,391)
Net cash used in investing activities	(41,211,268)	(3,233,927)
FINANCING ACTIVITIES
Proceeds from exercise of warrants		614,368
Taxes paid related to net share settlement of equity awards	(9,810)	(17,709)
Employee tax withholdings paid on equity awards	(204,614)	(698,398)
Tax shares sold to pay for employee tax withholdings on equity awards	338,486	336,754
Net cash provided by financing activities	124,062	235,015
Net decrease in cash and cash equivalents	(55,184,374)	(7,891,205)
Cash and cash equivalents at beginning of period	112,750,980	66,561,683
Cash and cash equivalents at end of period	57,566,606	58,670,478
Supplemental Disclosures of Cash Flow Information
Cash paid for taxes	50,000	50,000
Supplemental Schedule of Non-Cash Investing and Financing Activities
Accrued expenses from consultants settled with Common Stock	75,000	55,000
Sale of treasury shares pending settlement		2,144
Property and equipment included in accounts payable and accrued expenses	$ 115,637

Nature of Operations

3 Months Ended

Jan. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations

1. NATURE OF OPERATIONS

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery system. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (“Lm” or “Listeria” or “Lm Technology^TM”) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors.

Axalimogene filolisbac is our lead Lm–based product candidate for the treatment of Human Papilloma Virus (“HPV”) - associated cancers. The Company completed a randomized Phase 2 study in 110 patients with recurrent cervical cancer that was shown to have a manageable safety profile, apparent improved survival and objective tumor responses. In addition, the Gynecologic Oncology Group (“GOG”) Foundation, Inc., now part of NRG Oncology, conducted a cooperative group / Company sponsored Phase 2 open-label clinical study of axalimogene filolisbac in patients with persistent or recurrent cervical cancer with documented disease progression. The study, known as GOG-0265, has successfully completed the first and second stages in its Simon 2-stage design. The results from both stages combined demonstrate a 38% 12-month overall survival. Upon early closure of this study, a total of 50 patients were dosed resulting in a 12-month survival rate of 38.0% with a manageable safety profile. The Company has initiated a registrational Phase 3 clinical trial for the adjuvant treatment of women with high-risk locally advanced cervical cancer and is planning to initiate a registrational Phase 3 clinical trial in 2017 in the metastatic cervical cancer setting. The Company also plans to pursue registrational opportunities in Europe in 2017 for the metastatic cervical cancer setting.

Axalimogene filolisbac has received United States Food and Drug Administration (“FDA”) orphan drug designation for three HPV-associated cancers: cervical, head and neck, and anal cancer, and has received European Medicines Agency (“EMA”) orphan drug designation for anal cancer. Axalimogene filolisbac has been designated by the FDA as a Fast Track product for adjuvant therapy for high-risk locally advanced cervical cancer patients. It has also been classified as an advanced-therapy medicinal product (“ATMP”) for the treatment of cervical cancer by the European Medicines Agency’s Committee for Advanced Therapies (“CAT”). Axalimogene filolisbac is subject to an agreement with the FDA, under the Special Protocol Assessment (“SPA”) process, for the Phase 3 AIM2CERV trial in patients with high-risk, locally advanced cervical cancer. It is also being evaluated in Company-sponsored trials executed under an Investigational New Drug (“IND”) which include the following: (i) a Phase 1/2 clinical trial alone and in combination with MedImmune, LLC’s (“MedImmune”) investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), in patients with previously treated metastatic cervical cancer or patients with HPV-associated head and neck cancer; and (ii) a single arm Phase 2 monotherapy study in patients with metastatic anal cancer. In addition to the Company-sponsored trials, axalimogene filolisbac is also being evaluated in two investigator-initiated clinical trials as follows: neoadjuvant treatment of HPV-positive head and neck cancer (Mount Sinai & Baylor College of Medicine), and locally advanced high risk anal cancer (Brown University).

ADXS-PSA is the Company’s Lm–based product candidate designed to target the Prostate Specific Antigen (“PSA”) associated with prostate cancer which is being evaluated in a Phase 1/2 clinical trial alone and in combination with KEYTRUDA® (pembrolizumab), Merck & Co.’s (“Merck”) humanized monoclonal antibody against PD-1, in patients with previously treated metastatic castration-resistant prostate cancer.

ADXS-HER2 is the Company’s Lm-based product candidate designed for the treatment of Human Epidermal Growth Factor Receptor 2 (“HER2”) expressing cancers, including human and canine osteosarcoma. ADXS-HER2 is being evaluated in a Phase 1b clinical trial in patients with metastatic HER2 expressing solid tumors. The Company received orphan drug designation from both the FDA and EMA for ADXS-HER2 in osteosarcoma and have received Fast Track designation from the FDA for patients with newly-diagnosed, non-metastatic, surgically-resectable osteosarcoma. Clinical research with ADXS-HER2 in canine osteosarcoma is being developed by the Company’s pet therapeutic partner, Aratana Therapeutics Inc. (“Aratana”), who holds exclusive rights to develop and commercialize ADXS-HER2 and three other Lm -LLO immunotherapies for pet health applications. Aratana has announced that a product license application for use of ADXS-HER2 in the treatment of canine osteosarcoma has been filed with the United States Department of Agriculture (“USDA”). Aratana received communication from the USDA in March 2015 stating that the previously submitted efficacy data for product licensure for AT-014 (ADXS-HER2), the cancer immunotherapy for canine osteosarcoma, was accepted and that it provides a reasonable expectation of efficacy that supports conditional licensure. While additional steps need to be completed, including in the areas of manufacturing and safety, Aratana anticipates that AT-014 could receive conditional licensure from the USDA in 2017.

ADXS-NEO is the Company’s individual Lm-based antigen delivery technology combined with a fusion protein based on information captured by comparing a patient’s own DNA with the DNA from that patient’s tumor. The FDA has cleared the Company’s IND application of a new precision immunotherapy for the treatment of cancers. The Company plans to initiate a Phase 1 study in 2017.

The Company has focused its development efforts on establishing a drug development pipeline that incorporates this technology into therapeutic cancer immunotherapies, with clinical trials currently targeting HPV-associated cancers (cervical cancer, head and neck cancer, and anal cancer), prostate cancer, and osteosarcoma. Although no immunotherapies have been commercialized to date, the Company continues to invest in research and development to advance the technology and make it available to patients with many different types of cancer. Pipeline development and the further exploration of the technology for advancement entails risk and expense. The Company anticipates that its ongoing operational costs will increase significantly as it continues conducting and expanding its clinical development programs. In addition to its existing single antigen vectors that target one tumor associated antigen, the Company is actively engaged in the development of new constructs that will address multiple targets that are common to tumor types, as well as mutation-associated epitopes that are specific to an individual patient’s tumor. The Company is also leveraging its Lm Technology™ to target common (public or shared) mutations (hotspots) in tumor driver genes. The Company is exploring a preclinical infectious disease program as well to examine potential applications of its Lm Technology™. Lastly, the Company is continuing to build-out its manufacturing capabilities at the state-of-the-art manufacturing facility in Princeton, NJ, to produce supplies for its neoepitope and other development programs.

Liquidity and Financial Condition

The Company’s products are being developed and have not generated significant revenues. As of January 31, 2017, the Company had approximately $136.9 million in cash, cash equivalents and investments on its balance sheet. The Company believes its current cash position is sufficient to fund its business plan approximately through the second quarter of fiscal 2019. The estimate is based on assumptions that may prove to be wrong, and the Company could use available capital resources sooner than currently expected. Because of the numerous risks and uncertainties associated with the development and commercialization of its product candidates, the Company is unable to estimate the amount of increased capital outlays and operating expenses associated with completing the development of its current product candidates.

The Company recognizes it may need to raise additional capital in order to continue to execute its business plan. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to scale back its business plan.

Summary of Significant Accounting Policies and Basis of Presentation

3 Months Ended

Jan. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies and Basis of Presentation

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Basis of Presentation - Unaudited Interim Financial Information

The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information, and in accordance with the rules and regulations of the SEC with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to represent a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company for the year ended October 31, 2016 and notes thereto contained in the Company’s annual report on Form 10-K for the year ended October 31, 2016, as filed with the SEC on January 9, 2017.

The information presented in the accompanying unaudited condensed balance sheet as of October 31, 2016 has been derived from the Company’s October 31, 2016 audited financial statements.

Estimates

The preparation of financial statements in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ substantially from these estimates. Significant estimates include the fair value and recoverability of the carrying value of property and equipment intangible assets (patents and licenses), the fair value of investments, the fair value of options, the fair value of warrants and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results may differ from estimates.

Revenue Recognition

The Company is expected to derive the majority of its revenue from patent licensing and research and development services associated with patent licensing. In general, these revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. The intellectual property rights granted may be perpetual in nature, or upon the final milestones being met, or can be granted for a defined, relatively short period of time, with the licensee possessing the right to renew the agreement at the end of each contractual term for an additional minimum upfront payment. The Company recognizes licensing fees when there is persuasive evidence of a licensing arrangement, fees are fixed or determinable, delivery has occurred and collectability is reasonably assured.

Revenue associated with nonrefundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue on a straight-line basis over the expected period of performance.

Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved and the milestone payments are due and collectible. If not deemed substantive, the Company recognizes such milestones as revenue on a straight-line basis over the remaining expected performance period under the arrangement. All such recognized revenues are included in collaborative licensing and development revenue in the Company’s statements of operations.

Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, and the other milestones in the arrangement and the related risk associated with the achievement of the milestone and any ongoing research and development or other services are priced at fair value.

If product development is successful, the Company will recognize revenue from royalties based on licensees’ sales of its products or products using its technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. If royalties cannot be reasonably estimated or collectability of a royalty amount is not reasonably assured, royalties are recognized as revenue when the cash is received.

Deferred revenue represents the portion of payments received for which the earnings process has not been completed. Deferred revenue expected to be recognized within the next 12 months is classified as a current liability.

An allowance for doubtful accounts is established based on the Company’s best estimate of the amount of probable credit losses in the Company’s existing license fee receivables, using historical experience. The Company reviews its allowance for doubtful accounts periodically. Past due accounts are reviewed individually for collectability. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. To date, this is yet to occur.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of January 31, 2017 and October 31, 2016, the Company had approximately $49.0 million and $106.7 million in cash equivalents.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $53.9 million is subject to credit risk at January 31, 2017. However, these cash balances are maintained at creditworthy financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

Fair Value of Financial Instruments

The carrying amounts of financial instruments, including cash and accounts payable approximated fair value as of the balance sheet date presented, because of the relatively short maturity dates on these instruments. The carrying amounts of the financing arrangements issued approximate fair value as of the balance sheet date presented, because interest rates on these instruments approximate market interest rates after consideration of stated interest rates, anti-dilution protection and associated warrants.

Net Loss per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential Common Stock outstanding during the period. In the case of a net loss the impact of the potential Common Stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential Common Stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share.

	As of January 31,
	2017		2016
Warrants		3,110,575		3,110,575
Stock Options		3,897,558		3,357,074
Restricted Stock Units		1,111,059		975,256
Convertible Debt (using the if-converted method)		-		1,576
Total		8,119,192		7,442,905

Stock Based Compensation

The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally measured based on contractual terms. The fair value amount is then recognized over the requisite service period, usually the vesting period, in both research and development expenses and general and administrative expenses on the statement of operations, depending on the nature of the services provided by the employees or consultants.

The process of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over their requisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock option awards on the date of grant using the Black Scholes Model (“BSM”) for the remaining awards, which requires that the Company makes certain assumptions regarding: (i) the expected volatility in the market price of its Common Stock; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensation expense could change materially for future grants.

The Company accounts for stock-based compensation using fair value recognition and records stock-based compensation as a charge to earnings net of forfeited awards. As such, the Company recognizes stock-based compensation cost only for those stock-based awards that vest over their requisite service period, based on the vesting provisions of the individual grants.

Recent Accounting Pronouncements

In May 2014, as part of its ongoing efforts to assist in the convergence of GAAP and International Financial Reporting Standards, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers”, which is a new standard related to revenue recognition. Under the new standard, recognition of revenue occurs when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. The standard must be adopted using either a full retrospective approach for all periods presented in the period of adoption or a modified retrospective approach. In July 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers - Deferral of the Effective Date”, which defers the implementation of this new standard to be effective for fiscal years beginning after December 15, 2017. Early adoption is permitted effective January 1, 2017. In March 2016, the FASB issued ASU 2016-08, “Principal versus Agent Considerations”, which clarifies the implementation guidance on principal versus agent considerations in the new revenue recognition standard pursuant to ASU 2014-09. In April 2016, the FASB issued ASU 2016-10, “Identifying Performance Obligations and Licensing”, and in May 2016, the FASB issued ASU 2016-12, “Narrow-Scope Improvements and Practical Expedients”, which amend certain aspects of the new revenue recognition standard pursuant to ASU 2014-09. We are currently evaluating which transition approach we will utilize and the impact of adopting this accounting standard on our unaudited condensed financial statements.

In February 2016, the FASB issued ASU 2016-02, “Leases (“Topic 842”) (“ASU 2016-02”). The standard amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective beginning in the first quarter of 2019. Early adoption of ASU 2016-02 is permitted. The new leases standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company is currently evaluating the impact of adopting ASU 2016-02 on the Company’s financial statements.

In March 2016, the FASB issued ASU 2016-09, “Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. This ASU makes targeted amendments to the accounting for employee share-based payments. This guidance is to be applied using various transition methods such as full retrospective, modified retrospective, and prospective based on the criteria for the specific amendments as outlined in the guidance. The guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2016. Early adoption is permitted, as long as all of the amendments are adopted in the same period. The Company has evaluated this standard and chose early adoption effective March 30, 2016. The Company elected to record for forfeitures as they occur. This ASU has not had a material impact on the Company’s financial statements.

In June 2016, the FASB issued Accounting Standards Update ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”. The standard significantly changes how entities will measure credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. The standard will replace today’s “incurred loss” approach with an “expected loss” model for instruments measured at amortized cost. For available-for-sale debt securities, entities will be required to record allowances rather than reduce the carrying amount, as they do today under the other-than-temporary impairment model. It also simplifies the accounting model for purchased credit-impaired debt securities and loans. This ASU is effective for annual periods beginning after December 15, 2019, and interim periods therein. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods therein. This ASU is not expected to have a material impact on the Company’s financial statements.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Investments

3 Months Ended

Jan. 31, 2017

Schedule of Investments [Abstract]

Investments

3. INVESTMENTS

The following table summarizes the Company’s investment securities at amortized cost as of January 31, 2017 and October 31, 2016:

	January 31, 2017
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross unrealized holding losses		Estimated fair value
Short-term investments:
Certificates of Deposit	$	25,010,270	$	-	$	-	$	25,010,270
Domestic Governmental Agency Loans		5,664,336		49		512		5,663,873
U.S Treasury Notes		48,620,773		3,591		8,569		48,615,795
Total short-term investment securities	$	79,295,379	$	3,640	$	9,081	$	79,289,938

	October 31, 2016
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross unrealized holding losses		Estimated fair value
Short-term investments:
Certificates of Deposit	$	10,737,563	$	-	$	-	$	10,737,563
Domestic Governmental Agency Loans		2,500,000		-		250		2,499,750
U.S Treasury Notes		26,098,985		2,404		7,556		26,093,833
Total short-term investment securities	$	39,336,548	$	2,404	$	7,806	$	39,331,146

All of the Company’s investments mature within the next 12 months.

Property and Equipment

3 Months Ended

Jan. 31, 2017

Property, Plant and Equipment [Abstract]

Property and Equipment

4. PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

	January 31, 2017			October 31, 2016

Leasehold Improvements	$	1,972,498		$	1,835,602
Laboratory Equipment		2,839,843			2,038,704
Furniture and Fixtures		637,761			549,025
Computer Equipment		285,209			240,910
Construction in Progress	$	91,661			151,368
Total Property and Equipment		5,826,972			4,815,609
Accumulated Depreciation and Amortization		(584,115	)		(426,535	)
Net Property and Equipment	$	5,242,857		$	4,389,074

Depreciation expense for the three months ended January 31, 2017 and 2016 was $157,580 and $46,034 respectively.

Intangible Assets

3 Months Ended

Jan. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

5. INTANGIBLE ASSETS

Pursuant to our license agreement with the University of Pennsylvania, the Company is billed actual patent expenses as they are passed through from Penn and are billed directly from our patent attorney. The following is a summary of intangible assets as of the end of the following fiscal periods:

	January 31, 2017			October 31, 2016

License	$	776,992		$	776,992
Patents		5,056,042			4,980,610
Software		25,625			19,625
Total intangibles		5,858,659			5,777,227
Accumulated Amortization		(1,522,516	)		(1,448,106	)
Intangible Assets	$	4,336,143		$	4,329,121

The expirations of the existing patents range from 2017 to 2037 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. No patent applications with future value were abandoned or expired and charged to expense in the three months ended January 31, 2017 or 2016. Amortization expense for intangible assets is included in research and development expenses and aggregated $74,410 and $57,946 for the three months ended January 31, 2017 and 2016, respectively.

Estimated amortization expense for the next five years is as follows:

Year ended October 31,

2017 (Remaining)	$	223,000
2018		299,000
2019		296,000
2020		290,000
2021		290,000

Accrued Expenses

3 Months Ended

Jan. 31, 2017

Payables and Accruals [Abstract]

Accrued Expenses

6. ACCRUED EXPENSES:

The following table represents the major components of accrued expenses:

	January 31, 2017		October 31, 2016

Salaries and Other Compensation	$	2,799,348	$	2,467,650
Vendors		2,882,186		2,098,792
Professional Fees		1,994,909		6,338,561
	$	7,676,443	$	10,905,003

Derivative Instruments

3 Months Ended

Jan. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments

7. DERIVATIVE INSTRUMENTS

Warrants

A summary of changes in warrants for the three months ended January 31, 2017 is as follows:

	Number of		Weighted-Average
	Warrants		Exercise Price
Outstanding Warrants at October 31, 2016		3,110,575	$	5.04
Issued		-	$	-
Exercised		-	$	-
Expired		-	$	-
Outstanding Warrants at January 31, 2017		3,110,575	$	5.04

At January 31, 2017 and October 31, 2016, the Company had approximately 3.09 million of its total 3.11 million outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the shareholders’ equity section of the balance sheet. The Company’s equity warrants can only be settled through the issuance of shares and are not subject to anti-dilution provisions.

Warrant Liability

At January 31, 2017 and October 31, 2016, the Company had approximately 18,000 of its total approximately 3.11 million outstanding warrants classified as liability warrants (liability warrants). The Company utilizes the BSM to calculate the fair value of these warrants at issuance and at each subsequent reporting date. The liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the Common Stock purchase warrant). Any changes in the fair value of the warrant liability (i.e. - the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported on the statement of operations.

At January 31, 2017 and October 31, 2016, the fair value of the warrant liability was $10,652 and $20,156, respectively. For the three months ended January 31, 2017 and 2016, the Company reported a gain of $9,504 and $49,282, respectively, due to changes in the fair value of the warrant liability. In determining the fair value of the warrant liability, at January 31, 2017 and October 31, 2016, the Company used the following inputs in its BSM:

	January 31, 2017			October 31, 2016

Exercise Price	$	10.63-18.75		$	10.63-18.75
Stock Price	$	8.96		$	8.09
Expected term		0.29-0.50 years			0.55-0.75 years
Expected Volatility		60.72%-81.39	%		81.84%-87.09	%
Risk Free Interest Rate		0.52%-0.64	%		0.51%-0.66	%

As of January 31, 2017, there were outstanding warrants to purchase 3,110,575 shares of the Company’s Common Stock with exercise prices ranging from $3.75 to $18.75 per share.

As of January 31, 2017, the aggregate intrinsic value of outstanding warrants was approximately $12,248,000.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Share Based Compensation

3 Months Ended

Jan. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share Based Compensation

8. SHARE BASED COMPENSATION

Employment Agreements

Management voluntarily purchases restricted stock directly from the Company at market price. The respective stock purchases occur on the last trading day of each month. This voluntary election is outlined in each of Daniel J. O’Connor, Chief Executive Officer and President, Robert G. Petit, Executive Vice President, Chief Scientific Officer, and Sara M. Bonstein, Executive Vice President and Secretary, Chief Financial Officer, (each an “Executive”), employment agreements. The table below reflects the purchases of each Executive:

	ANNUALIZED
	Annual Amount		For the Three Months Ended January 31, 2017
	to be Purchased		Gross Purchase				Net Purchase
Executive	$		$		# of shares		$		# of shares
Daniel J. O’Connor	$	54,547	$	13,627		1,713	$	10,644		1,335
Robert G. Petit	$	33,061	$	8,212		1,032	$	6,699		842
Sara M. Bonstein	$	29,261	$	7,333		922	$	5,033		623

For the three months ended January 31, 2017, the Company recorded stock compensation expense of $42,016 in the statement of operations for the portion of management salaries voluntarily paid in stock representing 5,316 shares of its Common Stock (4,071 shares on a net basis after employee payroll taxes). For the three months ended January 31, 2016, the Company recorded a similar stock compensation expense of $64,332 in the statement of operations representing 7,060 shares of its Common Stock (4,947 shares on a net basis after employee payroll taxes).

From 2013 to present, in addition to the purchases of Common Stock set forth in the above table, Mr. O’Connor has also purchased an additional 164,909 shares of Common Stock out of his personal funds at the then market price for an aggregate consideration of $689,004. These purchases consisted of the conversion of amounts due to Mr. O’Connor under a promissory note given by Mr. O’Connor to the Company in 2012 of approximately $66,500 for 21,091 shares, 2013 base salary which he elected to receive in Common Stock of approximately $186,555 for 34,752 shares (21,489 on a net basis after employee payroll taxes), 2013 and 2014 cash bonuses voluntarily requested to receive in equity of $214,359 for 62,064 shares (57,990 on a net basis after employee payroll taxes), fiscal 2014 voluntary request to purchase stock directly from the Company at market price purchases of $68,750 for 21,687 shares (15,950 on a net basis after employee payroll taxes), fiscal 2015 voluntary request to purchase stock directly from the Company at market price purchases of $88,840 for 8,482 shares (7,556 on a net basis after employee payroll taxes), and purchases of the Company’s Common Stock in the October 2013 and March 2014 public offerings of 13,500 shares for $54,000 and 3,333 shares for $10,000.

Restricted Stock Units (RSUs)

A summary of the Company’s RSU activity and related information for the three months ended January 31, 2017 is as follows:

	Number of			Weighted-Average
	RSUs			Grant Date Fair Value

Balance at October 31, 2016:		719,448		$	10.77
Granted		487,282		$	8.35
Vested		(87,235	)	$	8.62
Cancelled		(8,436	)	$	8.31
Balance at January 31, 2017		1,111,059		$	9.89

As of January 31, 2017, there was approximately $9,175,000 of unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately 2.28 years.

As of January 31, 2017, the aggregate intrinsic value of non-vested RSUs was approximately $9,955,000.

Employee Stock Awards

During the three months ended January 31, 2017, 88,660 shares of Common Stock were issued to executives and employees related to vested incentive retention awards, employment inducements and employee excellence awards. Total stock compensation expense associated with these awards was $1,314,623.

During the three months ended January 31, 2016, 238,129 shares of Common Stock were issued to executives and employees related to vested incentive retention awards, employment inducements and employee excellence awards. Total stock compensation expense associated with these awards was $1,857,076.

Furthermore, non-executive employees were entitled to receive a performance-based year-end cash bonus. Several non-executive employees voluntarily requested to be paid all or a portion of their cash bonus in the Company’s Common Stock instead of cash. During the three months ended January 31, 2016, the Company recorded a liability on its balance sheet for $102,022 for bonuses that will be paid in Common Stock.

Director Stock Awards

During the three months ended January 31, 2017, total stock compensation expense to the Directors for amortization of unvested awards was $101,628.

During the three months ended January 31, 2016, 31,767 shares of Common Stock were issued to the Directors for compensation related to board and committee membership. Total stock compensation expense to the Directors was $311,205.

Stock Options

A summary of changes in the stock option plan for the three months ended January 31, 2017 is as follows:

	Number of			Weighted-Average
	Options			Exercise Price
Outstanding at October 31, 2016:		3,351,795		$	13.31
Granted		556,952		$	7.71
Exercised		-		$	-
Expired		(11,189	)	$	17.88
Outstanding at January 31, 2017		3,897,558		$	12.50
Vested and Exercisable at January 31, 2017		1,800,252		$	13.46

Total compensation cost related to the Company’s outstanding stock options, recognized in the statement of operations for the three months ended January 31, 2017 was $3,183,458. For the three months ended January 31, 2016, compensation cost related to the Company’s outstanding stock options was $6,671,986.

During the three months ended January 31, 2017, 556,952 options were granted with a total grant date fair value of $3,542,215. During the three months ended January 31, 2016, 1,385,000 options were granted with a total grant date fair value of $14,837,970.

As of January 31, 2017, there was approximately $19,688,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.65 years.

As of January 31, 2017, the aggregate intrinsic value of vested and exercisable options was approximately $74,000.

In determining the fair value of the stock options granted during the three months ended January 31, 2017 and 2016, the Company used the following inputs in its BSM:

	Three Months Ended January 31,
	2017			2016

Expected Term		5.50-6.50 years			5.51-6.51 years
Expected Volatility		107.07%-110.93	%		109.23%-115.25	%
Expected Dividends		0	%		0	%
Risk Free Interest Rate		1.26-1.58	%		1.65-2.00	%

Shares Issued to Consultants

During the three months ended January 31, 2017, 32,500 shares of Common Stock valued at $313,600 were issued to consultants for services, of which $75,000 represented shares issued for amounts previously accrued. The Company recorded a liability on its balance sheet for $230,100 for shares earned pursuant to consulting agreements but not delivered. The common stock share values were based on the dates the shares vested.

During the three months ended January 31, 2016, 23,124 shares of Common Stock valued at $275,087 were issued to consultants for services, of which $55,000 represented shares issued for amounts previously accrued. The Company recorded a liability on its balance sheet for $302,300 for shares earned pursuant to consulting agreements but not delivered. The common stock share values were based on the dates the shares vested.

The following table summarizes share-based compensation expense included in the Statement of Operations by expense category for the three months ended January 31, 2017 and 2016, respectively:

	Three Months Ended January 31,
	2017		2016
Research and development	$	1,222,483	$	5,106,640
General and administrative		3,887,942		4,422,368
Total	$	5,110,425	$	9,529,008

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Commitments and Contingencies

3 Months Ended

Jan. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

9. COMMITMENTS AND CONTINGENCIES:

Legal Proceedings

Knoll

On August 21, 2015, Knoll Capital Management L.P. (“KCM”) filed a complaint against the Company in the Delaware Court of Chancery. The complaint alleges the existence of an oral agreement for the purchase by Knoll from the Company of 1,666,666.67 shares of Company stock at a price of $3.00 per share. KCM alleges that the Company breached this alleged agreement and seeks specific performance or, alternatively, money damages for breach of contract. KCM served the Company with the complaint on August 31, 2015, and then served an amended complaint on October 16, 2015. The Company moved to dismiss the amended complaint on October 26, 2015 and that motion was denied on January 29, 2016. The Company filed an answer to the amended complaint on February 12, 2016. The parties are currently in the process of producing document discovery. A bench trial has been set for November 7, 2017. The Company intends to defend itself vigorously.

Larkin and Bono

On August 20, 2015, a derivative complaint was filed by a purported Company shareholder in the United States District Court for the District of New Jersey styled David Bono v. O’Connor, et al., Case No. 3:15-CV-006326-FLW-DEA (D.N.J. Aug. 20, 2015) (the “Bono Action”). The complaint is based on general allegations related to certain stock options granted to the individual defendants and generally alleges counts for breaches of fiduciary duty and unjust enrichment. The complaint also alleges additional claims for violation of Section 14(a) of the Securities Exchange Act of 1934 and for waste of corporate assets. The complaint seeks damages and costs of an unspecified amount, disgorgement of compensation obtained by the individual defendants, and injunctive relief.

Defendants filed a motion to dismiss the Bono Action. On May 23, 2016, the United States District Court for the District of New Jersey issued an opinion and order granting in part and denying in part defendants’ motion to dismiss. The court denied the motion to dismiss as to the breach of fiduciary duty claim and unjust enrichment claim against the three members of the Compensation Committee, but dismissed without prejudice the breach of fiduciary duty and unjust enrichment claims against the other eight individual defendants. The court dismissed without prejudice the Section 14(a) disclosure claim and waste claims against all defendants. On October 5, 2016, the court denied plaintiff’s motion for reconsideration of its May 23 order.

At this stage of the proceeding, the Company does not express any opinion as to likely outcome, but the Company intends to defend the action vigorously.

General

The Company is from time to time involved in legal proceedings in the ordinary course of its business. The Company does not believe that any of these claims and proceedings against it is likely to have, individually or in the aggregate, a material adverse effect on its financial condition or results of operations.

Operating Leases

The Company’s corporate offices are currently located at 305 College Road East, Princeton, New Jersey 08540.

Future minimum payments of the Company’s operating leases are as follows:

Year ended October 31,

2017 (Remaining)	$	736,397
2018		1,041,895
2019		1,107,385
2020		1,232,907
2021		1,317,640
Thereafter		5,747,340
Total		11,183,564

Fair Value

3 Months Ended

Jan. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value

10. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

The following table provides the liabilities carried at fair value measured on a recurring basis as of January 31, 2017 and October 31, 2016:

January 31, 2017	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $10.63- $18.75 from February 2017 through August 2017	$	-	$	-	$	10,652	$	10,652

October 31, 2016	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $10.63- $18.75 from November 2016 through August 2017	$	-	$	-	$	20,156	$	20,156

Common stock warrant liability:

	January 31, 2017
	(Unaudited)
Beginning balance: October 31, 2016	$	20,156
Change in fair value		(9,504	)

Balance at January 31, 2017	$	10,652

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Subsequent Events

3 Months Ended

Jan. 31, 2017

Subsequent Events [Abstract]

Subsequent Events

11. SUBSEQUENT EVENTS

On February 27, 2017, the Company entered into a license agreement with Sellas Life Science Group (“Sellas”) to develop a novel cancer immunotherapy agent using Advaxis’ proprietary Lm-based antigen delivery technology with SELLAS’ patented WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S)). Pursuant to the agreement, Advaxis will conduct all pre-clinical activities required for an IND filing and Sellas will be responsible for all clinical development and commercial activities. Advaxis will receive future payments of up to $358 million from SELLAS if certain development, regulatory, and commercial milestones are met. SELLAS has agreed to pay Advaxis single-digit to low double-digit royalties based on worldwide net sales upon commercialization. If SELLAS sublicenses its rights, Advaxis will receive a percentage of applicable sublicense revenue paid.

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Jan. 31, 2017

Accounting Policies [Abstract]

Basis of Presentation - Unaudited Interim Financial Information

Basis of Presentation - Unaudited Interim Financial Information

The information presented in the accompanying unaudited condensed balance sheet as of October 31, 2016 has been derived from the Company’s October 31, 2016 audited financial statements.

Estimates

Estimates

Revenue Recognition

Revenue Recognition

Cash and Cash Equivalents

Cash and Cash Equivalents

Concentration of Credit Risk

Concentration of Credit Risk

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Net Loss per Share

Net Loss per Share

	As of January 31,
	2017		2016
Warrants		3,110,575		3,110,575
Stock Options		3,897,558		3,357,074
Restricted Stock Units		1,111,059		975,256
Convertible Debt (using the if-converted method)		-		1,576
Total		8,119,192		7,442,905

Stock Based Compensation

Stock Based Compensation

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Jan. 31, 2017

Accounting Policies [Abstract]

Schedule of Common Stock Excluded from Diluted Net Loss Per Share

The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share.

	As of January 31,
	2017		2016
Warrants		3,110,575		3,110,575
Stock Options		3,897,558		3,357,074
Restricted Stock Units		1,111,059		975,256
Convertible Debt (using the if-converted method)		-		1,576
Total		8,119,192		7,442,905

Investments (Tables)

3 Months Ended

Jan. 31, 2017

Schedule of Investments [Abstract]

Schedule of Investment Securities at Amortized

The following table summarizes the Company’s investment securities at amortized cost as of January 31, 2017 and October 31, 2016:

	January 31, 2017
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross unrealized holding losses		Estimated fair value
Short-term investments:
Certificates of Deposit	$	25,010,270	$	-	$	-	$	25,010,270
Domestic Governmental Agency Loans		5,664,336		49		512		5,663,873
U.S Treasury Notes		48,620,773		3,591		8,569		48,615,795
Total short-term investment securities	$	79,295,379	$	3,640	$	9,081	$	79,289,938

	October 31, 2016
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross unrealized holding losses		Estimated fair value
Short-term investments:
Certificates of Deposit	$	10,737,563	$	-	$	-	$	10,737,563
Domestic Governmental Agency Loans		2,500,000		-		250		2,499,750
U.S Treasury Notes		26,098,985		2,404		7,556		26,093,833
Total short-term investment securities	$	39,336,548	$	2,404	$	7,806	$	39,331,146

Property and Equipment (Tables)

3 Months Ended

Jan. 31, 2017

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment consists of the following:

	January 31, 2017			October 31, 2016

Leasehold Improvements	$	1,972,498		$	1,835,602
Laboratory Equipment		2,839,843			2,038,704
Furniture and Fixtures		637,761			549,025
Computer Equipment		285,209			240,910
Construction in Progress	$	91,661			151,368
Total Property and Equipment		5,826,972			4,815,609
Accumulated Depreciation and Amortization		(584,115	)		(426,535	)
Net Property and Equipment	$	5,242,857		$	4,389,074

Intangible Assets (Tables)

3 Months Ended

Jan. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets

The following is a summary of intangible assets as of the end of the following fiscal periods:

	January 31, 2017			October 31, 2016

License	$	776,992		$	776,992
Patents		5,056,042			4,980,610
Software		25,625			19,625
Total intangibles		5,858,659			5,777,227
Accumulated Amortization		(1,522,516	)		(1,448,106	)
Intangible Assets	$	4,336,143		$	4,329,121

Schedule of Amortization Expense

Estimated amortization expense for the next five years is as follows:

Year ended October 31,

2017 (Remaining)	$	223,000
2018		299,000
2019		296,000
2020		290,000
2021		290,000

Accrued Expenses (Tables)

3 Months Ended

Jan. 31, 2017

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

The following table represents the major components of accrued expenses:

	January 31, 2017		October 31, 2016

Salaries and Other Compensation	$	2,799,348	$	2,467,650
Vendors		2,882,186		2,098,792
Professional Fees		1,994,909		6,338,561
	$	7,676,443	$	10,905,003

Derivative Instruments (Tables)

3 Months Ended

Jan. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Warrants Activity

A summary of changes in warrants for the three months ended January 31, 2017 is as follows:

	Number of		Weighted-Average
	Warrants		Exercise Price
Outstanding Warrants at October 31, 2016		3,110,575	$	5.04
Issued		-	$	-
Exercised		-	$	-
Expired		-	$	-
Outstanding Warrants at January 31, 2017		3,110,575	$	5.04

Schedule of Fair Value of Warrant Liability

In determining the fair value of the warrant liability, at January 31, 2017 and October 31, 2016, the Company used the following inputs in its BSM:

	January 31, 2017			October 31, 2016

Exercise Price	$	10.63-18.75		$	10.63-18.75
Stock Price	$	8.96		$	8.09
Expected term		0.29-0.50 years			0.55-0.75 years
Expected Volatility		60.72%-81.39	%		81.84%-87.09	%
Risk Free Interest Rate		0.52%-0.64	%		0.51%-0.66	%

Share Based Compensation (Tables)

3 Months Ended

Jan. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Allocation of Base Salary

The table below reflects the purchases of each Executive:

	ANNUALIZED
	Annual Amount		For the Three Months Ended January 31, 2017
	to be Purchased		Gross Purchase				Net Purchase
Executive	$		$		# of shares		$		# of shares
Daniel J. O’Connor	$	54,547	$	13,627		1,713	$	10,644		1,335
Robert G. Petit	$	33,061	$	8,212		1,032	$	6,699		842
Sara M. Bonstein	$	29,261	$	7,333		922	$	5,033		623

Summary of RSU Activity and Related Information

A summary of the Company’s RSU activity and related information for the three months ended January 31, 2017 is as follows:

	Number of			Weighted-Average
	RSUs			Grant Date Fair Value

Balance at October 31, 2016:		719,448		$	10.77
Granted		487,282		$	8.35
Vested		(87,235	)	$	8.62
Cancelled		(8,436	)	$	8.31
Balance at January 31, 2017		1,111,059		$	9.89

Summary of Changes in Stock Option Plan

A summary of changes in the stock option plan for the three months ended January 31, 2017 is as follows:

	Number of			Weighted-Average
	Options			Exercise Price
Outstanding at October 31, 2016:		3,351,795		$	13.31
Granted		556,952		$	7.71
Exercised		-		$	-
Expired		(11,189	)	$	17.88
Outstanding at January 31, 2017		3,897,558		$	12.50
Vested and Exercisable at January 31, 2017		1,800,252		$	13.46

Summary of Fair Value of Stock Options Granted of BSM

In determining the fair value of the stock options granted during the three months ended January 31, 2017 and 2016, the Company used the following inputs in its BSM:

	Three Months Ended January 31,
	2017			2016

Expected Term		5.50-6.50 years			5.51-6.51 years
Expected Volatility		107.07%-110.93	%		109.23%-115.25	%
Expected Dividends		0	%		0	%
Risk Free Interest Rate		1.26-1.58	%		1.65-2.00	%

Summary of Share-based Compensation Expense

The following table summarizes share-based compensation expense included in the Statement of Operations by expense category for the three months ended January 31, 2017 and 2016, respectively:

	Three Months Ended January 31,
	2017		2016
Research and development	$	1,222,483	$	5,106,640
General and administrative		3,887,942		4,422,368
Total	$	5,110,425	$	9,529,008

Commitments and Contingencies (Tables)

3 Months Ended

Jan. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Summary of Future Minimum Payments of Operating Leases

Future minimum payments of the Company’s operating leases are as follows:

Year ended October 31,

2017 (Remaining)	$	736,397
2018		1,041,895
2019		1,107,385
2020		1,232,907
2021		1,317,640
Thereafter		5,747,340
Total		11,183,564

Fair Value (Tables)

3 Months Ended

Jan. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring Basis

The following table provides the liabilities carried at fair value measured on a recurring basis as of January 31, 2017 and October 31, 2016:

January 31, 2017	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $10.63- $18.75 from February 2017 through August 2017	$	-	$	-	$	10,652	$	10,652

October 31, 2016	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $10.63- $18.75 from November 2016 through August 2017	$	-	$	-	$	20,156	$	20,156

Schedule of Common Stock Warrant Liability

	January 31, 2017
	(Unaudited)
Beginning balance: October 31, 2016	$	20,156
Change in fair value		(9,504	)

Balance at January 31, 2017	$	10,652

Nature of Operations and Basis of Presentation (Details Narrative)	3 Months Ended
	Jan. 31, 2017 USD ($) Patients	Oct. 31, 2016 USD ($)	Jan. 31, 2016 USD ($)	Oct. 31, 2015 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of patients \| Patients	110
Cash and cash equivalents \| $	$ 57,566,606	$ 112,750,980	$ 58,670,478	$ 66,561,683

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Jan. 31, 2017	Oct. 31, 2016
Accounting Policies [Abstract]
Cash equivalents	$ 49,000,000	$ 106,700,000
Concentration of credit risk	$ 53,900,000

Summary of Significant Accounting Policies - Schedule of Common Stock Excluded from Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
Number of common stock excluded from diluted net loss per share	8,119,192	7,442,905
Warrants [Member]
Number of common stock excluded from diluted net loss per share	3,110,575	3,110,575
Stock Options [Member]
Number of common stock excluded from diluted net loss per share	3,897,558	3,357,074
Restricted Stock Units (RSUs) [Member]
Number of common stock excluded from diluted net loss per share	1,111,059	975,256
Convertible Debt [Member]
Number of common stock excluded from diluted net loss per share		1,576

Investments (Details Narrative)	3 Months Ended
Investments (Details Narrative)	Jan. 31, 2017
Schedule of Investments [Abstract]
Investments maturity description	All of the Company's investments mature within the next 12 months.

Investments - Schedule of Investment Securities at Amortized (Details) - USD ($)	3 Months Ended
	Jan. 31, 2017	Oct. 31, 2016
Amortized cost, as adjusted	$ 79,295,379	$ 39,336,548
Gross unrealized holding gains	3,640	2,404
Gross unrealized holding losses	9,081	7,806
Estimated fair value	79,289,938	39,331,146
Certificates of Deposit [Member]
Amortized cost, as adjusted	25,010,270	10,737,563
Gross unrealized holding gains
Gross unrealized holding losses
Estimated fair value	25,010,270	10,737,563
Domestic Governmental Agency Loans [Member]
Amortized cost, as adjusted	5,664,336	2,500,000
Gross unrealized holding gains	49
Gross unrealized holding losses	512	250
Estimated fair value	5,663,873	2,499,750
U.S Treasury Notes [Member]
Amortized cost, as adjusted	48,620,773	26,098,985
Gross unrealized holding gains	3,591	2,404
Gross unrealized holding losses	8,569	7,556
Estimated fair value	$ 48,615,795	$ 26,093,833

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Jan. 31, 2017	Jan. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 157,580	$ 46,034

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Jan. 31, 2017	Oct. 31, 2016
Property, Plant and Equipment [Abstract]
Leasehold Improvements	$ 1,972,498	$ 1,835,602
Laboratory Equipment	2,839,843	2,038,704
Furniture and Fixtures	637,761	549,025
Computer Equipment	285,209	240,910
Construction in Progress	91,661	151,368
Total Property and Equipment	5,826,972	4,815,609
Accumulated Depreciation and Amortization	(584,115)	(426,535)
Net Property and Equipment	$ 5,242,857	$ 4,389,074

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended
Intangible Assets (Details Narrative) - USD ($)	Jan. 31, 2017	Jan. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Finite lived patents expirations year	The expirations of the existing patents range from 2017 to 2037
Book value patent applications, net
Amortization of intangible assets	$ 74,410	$ 57,946

Intangible Assets - Summary of Intangible Assets (Details) - USD ($)	Jan. 31, 2017	Oct. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
License	$ 776,992	$ 776,992
Patents	5,056,042	4,980,610
Software	25,625	19,625
Total intangibles	5,858,659	5,777,227
Accumulated Amortization	(1,522,516)	(1,448,106)
Intangible Assets	$ 4,336,143	$ 4,329,121

Intangible Assets - Schedule of Amortization Expense (Details)	Oct. 31, 2016 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2017 (Remaining)	$ 223,000
2018	299,000
2019	296,000
2020	290,000
2021	$ 290,000

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Jan. 31, 2017	Oct. 31, 2016
Payables and Accruals [Abstract]
Salaries and other compensation	$ 2,799,348	$ 2,467,650
Vendors	2,882,186	2,098,792
Professional fees	1,994,909	6,338,561
Total Accrued Expenses	$ 7,676,443	$ 10,905,003

Derivative Instruments (Details Narrative) - USD ($)	3 Months Ended
Derivative Instruments (Details Narrative) - USD ($)	Jan. 31, 2017	Jan. 31, 2016	Oct. 31, 2016
Warrants outstanding	3,110,575		3,110,575
Fair value of warrant liability	$ 10,652		$ 20,156
Gain (loss) on change in fair value of warrant liability	$ 9,504	$ 49,282
Exercise price per share	$ 5.04		$ 5.04
Aggregate intrinsic value of outstanding warrants	$ 12,248,000
Equity Warrants [Member]
Common stock purchase warrant	3,090,000		3,090,000
Warrants outstanding	3,110,000		3,110,000
Liability Warrants [Member]
Common stock purchase warrant	18,000		18,000
Warrants outstanding	3,110,000		3,110,000
Minimum [Member]
Exercise price per share	$ 10.63		$ 10.63
Maximum [Member]
Exercise price per share	18.75		$ 18.75
Warrants [Member] \| Minimum [Member]
Exercise price per share	3.75
Warrants [Member] \| Maximum [Member]
Exercise price per share	$ 18.75

Derivative Instruments - Schedule of Warrants Activity (Details)	3 Months Ended
	Jan. 31, 2017 $ / shares shares
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Number of Warrants, Outstanding, Beginning balance \| shares	3,110,575
Number of Warrants, Issued \| shares
Number of Warrants, Exercised \| shares
Number of Warrants, Expired \| shares
Number of Warrants, Outstanding, Ending balance \| shares	3,110,575
Weighted-Average Exercise Price, Outstanding, Beginning \| $ / shares	$ 5.04
Weighted-Average Exercise Price, Issued \| $ / shares
Weighted-Average Exercise Price, Exercised \| $ / shares
Weighted-Average Exercise Price, Expired \| $ / shares
Weighted-Average Exercise Price, Outstanding, Ending \| $ / shares	$ 5.04

Derivative Instruments - Schedule of Fair Value of Warrant Liability (Details) - $ / shares	3 Months Ended
	Jan. 31, 2017	Oct. 31, 2016
Stock Price	$ 8.96	$ 8.09
Minimum [Member]
Exercise Price	$ 10.63	$ 10.63
Expected term	3 months 15 days	6 months 18 days
Expected Volatility	60.72%	81.84%
Risk Free Interest Rate	0.52%	0.51%
Maximum [Member]
Exercise Price	$ 18.75	$ 18.75
Expected term	6 months	9 months
Expected Volatility	81.39%	87.09%
Risk Free Interest Rate	0.64%	0.66%

Share Based Compensation (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended
Share Based Compensation (Details Narrative) - USD ($)	Mar. 31, 2014	Oct. 31, 2013	Jan. 31, 2017	Jan. 31, 2016
Stock compensation expense			$ 42,016	$ 64,332
Share-based compensation, common stock, shares			5,316	7,060
Share-based compensation, shares on net basis after employee payroll taxes			4,071	4,947
Unrecognized compensation cost related to non-vested stock option awards			$ 19,688,000
Unrecognized compensation cost related to non-vested remaining weighted average vesting period			1 year 7 months 24 days
Options outstanding, intrinsic value			$ 74,000
Recorded a liability				$ 102,022
Compensation cost related to outstanding stock options			$ 3,183,458	$ 6,671,986
Number of options, granted			556,952	1,385,000
Fair value of option granted			$ 3,542,215	$ 14,837,970
Restricted Stock Units (RSUs) [Member]
Unrecognized compensation cost related to non-vested stock option awards			$ 9,175,000
Unrecognized compensation cost related to non-vested remaining weighted average vesting period			2 years 3 months 11 days
Options outstanding, intrinsic value			$ 9,955,000
Number of options, granted			487,282
Employee Stock Awards [Member]
Stock compensation expense			$ 1,314,623	$ 1,857,076
Share-based compensation, common stock, shares			88,660	238,129
2013 Base Salary Stock [Member]
Issuance of common stock shares			34,752
Number of stock shares issued during period amount			$ 186,555
Issuance of common stock net basis after taxes			21,489
2014 Cash Bonus Equity [Member]
Issuance of common stock shares			62,064
Number of stock shares issued during period amount			$ 214,359
Issuance of common stock net basis after taxes			57,990
2014 Voluntary Request To Purchase Of Equity [Member]
Issuance of common stock shares			21,687
Number of stock shares issued during period amount			$ 68,750
Issuance of common stock net basis after taxes			15,950
2015 Voluntary Request To Purchase Of Equity [Member]
Issuance of common stock shares			8,482
Number of stock shares issued during period amount			$ 88,840
Issuance of common stock net basis after taxes			7,556
Common Stock [Member]
Issuance of common stock shares	3,333	13,500
Number of stock shares issued during period amount	$ 10,000	$ 54,000
Promissory Note One [Member]
Issuance of common stock shares			21,091
Number of stock shares issued during period amount			$ 66,500
Daniel J. O' Connor [Member]
Issuance of common stock shares			164,909
Number of stock shares issued during period amount			$ 689,004
Directors [Member]
Stock compensation expense			$ 101,628	$ 311,205
Share-based compensation, common stock, shares				31,767
Consultants [Member]
Stock issued during period for services			32,500	23,124
Stock issued during period value for services			$ 313,600	$ 275,087
Consultants [Member]
Unrecognized compensation cost related to non-vested stock option awards			75,000	55,000
Recorded a liability			$ 230,100	$ 302,300

Share Based Compensation - Schedule of Allocation of Base Salary (Details) - USD ($)	3 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
Annual Amount to be Purchased	$ 5,110,425	$ 9,529,008
Daniel J. O' Connor [Member]
Annual Amount to be Purchased	54,547
Cumulative Gross Purchase	$ 13,627
Cumulative shares Gross Purchase	1,713
Cumulative Net Purchase	$ 10,644
Cumulative shares Net Purchase	1,335
Robert G. Petit [Member]
Annual Amount to be Purchased	$ 33,061
Cumulative Gross Purchase	$ 8,212
Cumulative shares Gross Purchase	1,032
Cumulative Net Purchase	$ 6,699
Cumulative shares Net Purchase	842
Sara M. Bonstein [Member]
Annual Amount to be Purchased	$ 29,261
Cumulative Gross Purchase	$ 7,333
Cumulative shares Gross Purchase	922
Cumulative Net Purchase	$ 5,033
Cumulative shares Net Purchase	623

Share Based Compensation - Summary of RSU Activity and Related Information (Details) - $ / shares	3 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
Beginning Balance	3,351,795
Number of RSUs Granted	556,952	1,385,000
Number of RSUs Vested
Ending Balance	3,897,558
Weighted-Average Exercise Price, Outstanding, Beginning	$ 13.31
Weighted-Average Exercise Price, Granted	7.71
Weighted-Average Exercise Price, Vested
Weighted-Average Exercise Price, Cancelled	17.88
Weighted-Average Exercise Price, Outstanding, Ending	$ 12.50
Restricted Stock Units (RSUs) [Member]
Beginning Balance	719,448
Number of RSUs Granted	487,282
Number of RSUs Vested	(87,235)
Number of RSUs Cancelled	(8,436)
Ending Balance	1,111,059
Weighted-Average Exercise Price, Outstanding, Beginning	$ 10.77
Weighted-Average Exercise Price, Granted	8.35
Weighted-Average Exercise Price, Vested	8.62
Weighted-Average Exercise Price, Cancelled	8.31
Weighted-Average Exercise Price, Outstanding, Ending	$ 9.89

Share Based Compensation - Summary of Changes in Stock Option Plan (Details) - $ / shares	3 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Beginning Balance	3,351,795
Number of Options, Granted	556,952	1,385,000
Number of Options, Exercised
Number of Options, Expired	(11,189)
Ending Balance	3,897,558
Number of Options, Vested and Exercisable	1,800,252
Weighted-Average Exercise Price, Outstanding, Beginning	$ 13.31
Weighted-Average Exercise Price, Granted	7.71
Weighted-Average Exercise Price, Exercised
Weighted-Average Exercise Price, Expired	17.88
Weighted-Average Exercise Price, Outstanding, Ending	12.50
Weighted-Average Exercise Price, Vested and Exercisable	$ 13.46

Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details)	3 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
Expected Volatility, Minimum	107.07%	109.23%
Expected Volatility, Maximum	110.93%	115.25%
Expected Dividends	0.00%	0.00%
Risk Free Interest Rate, Minimum	1.26%	1.65%
Risk Free Interest Rate, Maximum	1.58%	2.00%
Minimum [Member]
Expected Term	5 years 6 months	5 years 6 months 4 days
Maximum [Member]
Expected Term	6 years 6 months	6 years 6 months 4 days

Share Based Compensation - Summary of Share-based Compensation Expense (Details) - USD ($)	3 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
Share-based compensation expense	$ 5,110,425	$ 9,529,008
Research and Development [Member]
Share-based compensation expense	1,222,483	5,106,640
General and Administrative [Member]
Share-based compensation expense	$ 3,887,942	$ 4,422,368

Commitments and Contingencies (Details Narrative) - KCM [Member]	Aug. 21, 2015 $ / shares shares
Number of shares complaint alleges of common stock \| shares	1,666,666.67
Common stock price per share \| $ / shares	$ 3.00

Commitments and Contingencies - Summary of Future Minimum Payments of Operating Leases (Details)	Oct. 31, 2016 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2017 (Remaining)	$ 736,397
2018	1,041,895
2019	1,107,385
2020	1,232,907
2021	1,317,640
Thereafter	5,747,340
Total	$ 11,183,564

Fair Value - Fair Value, Liabilities Measured on Recurring Basis (Details) - USD ($)	Jan. 31, 2017	Oct. 31, 2016
Common stock warrant liability, warrants exercisable	$ 10,652	$ 20,156
Fair Value, Inputs, Level 1 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 3 [Member]
Common stock warrant liability, warrants exercisable	$ 10,652	$ 20,156

Fair Value - Fair Value, Liabilities Measured on Recurring Basis (Details) (Parenthetical) - $ / shares	3 Months Ended
	Jan. 31, 2017	Oct. 31, 2016
Exercise price per share	$ 5.04	$ 5.04
Warrants exercisable period	February 2017 through August 2017	November 2016 through August 2017
Minimum [Member]
Exercise price per share	$ 10.63	$ 10.63
Maximum [Member]
Exercise price per share	$ 18.75	$ 18.75

Fair Value - Schedule of Common Stock Warrant Liability (Details)	3 Months Ended
	Jan. 31, 2017 USD ($)
Fair Value Disclosures [Abstract]
Beginning balance	$ 20,156
Change in fair value	(9,504)
Ending balance	$ 10,652

Subsequent Events (Details Narrative)	Feb. 27, 2017 USD ($)
Subsequent Event [Member] \| License Agreement [Member] \| Sellas Life Science Group [Member]
Future Payments	$ 358,000,000

Derivative Instruments - Schedule of Warrants Activity (Details)	3 Months Ended
	Jan. 31, 2017 $ / shares shares
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Number of Warrants, Outstanding, Beginning balance \| shares	3,110,575
Number of Warrants, Issued \| shares
Number of Warrants, Exercised \| shares
Number of Warrants, Expired \| shares
Number of Warrants, Outstanding, Ending balance \| shares	3,110,575
Weighted-Average Exercise Price, Outstanding, Beginning \| $ / shares	$ 5.04
Weighted-Average Exercise Price, Issued \| $ / shares
Weighted-Average Exercise Price, Exercised \| $ / shares
Weighted-Average Exercise Price, Expired \| $ / shares
Weighted-Average Exercise Price, Outstanding, Ending \| $ / shares	$ 5.04